Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast cancer (TNBC) and HR-positive, HER2-negative (HR+/HER2−) early breast cancer. This review provides perspectives on some of the challenges related to identification of olaparib candidates, with a focus on the latest guidance for germline BRCA testing and considerations regarding high-risk disease definitions. Updated treatment pathways are explored for both disease states, including other adjuvant treatment options such as pembrolizumab, capecitabine, and abemaciclib. Gaps in the current literature regarding the sequential or combined use of these adjuvant therapies are noted and future, potentially informative, studies are briefly examined.

[1]  S. Loi,et al.  Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. , 2023, Journal of Clinical Oncology.

[2]  P. Neven,et al.  Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. , 2022, The Lancet. Oncology.

[3]  M. Piccart,et al.  Systemic therapy for early-stage breast cancer: learning from the past to build the future , 2022, Nature Reviews Clinical Oncology.

[4]  M. Piccart,et al.  Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Oza,et al.  Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Antonarakis,et al.  1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study , 2022, Annals of Oncology.

[7]  A. Tafreshi,et al.  Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. , 2022, European urology.

[8]  Y. Shentu,et al.  Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer , 2022, Clinical lung cancer.

[9]  N. Loman,et al.  VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer , 2022, Annals of Oncology.

[10]  C. Rudin,et al.  Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. , 2022, Clinical lung cancer.

[11]  F. Lu,et al.  A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles , 2022, Breast Cancer Research and Treatment.

[12]  P. Fasching,et al.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[13]  Reena Philip,et al.  FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Mandelker,et al.  Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer , 2021, Gynecologic Oncology Reports.

[15]  K. Murata,et al.  PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? , 2021, Cancers.

[16]  Frederick M. Howard,et al.  The emerging role of immune checkpoint inhibitors for the treatment of breast cancer , 2021, Expert opinion on investigational drugs.

[17]  M. Somerfield,et al.  Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Gómez,et al.  Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study , 2021, Clinical Trials.

[20]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[21]  A. Oza,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[22]  H. Rugo,et al.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer , 2021, Targeted Oncology.

[23]  W. Foulkes,et al.  Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. , 2021, European journal of cancer.

[24]  B. Karlan,et al.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  D. Cescon,et al.  68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC , 2020 .

[26]  S. Lheureux,et al.  ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer , 2020, Gynecologic Oncology.

[27]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Kohn,et al.  PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Oza,et al.  Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events , 2020, International Journal of Gynecological Cancer.

[30]  M. Somerfield,et al.  Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[32]  A. Tutt,et al.  A decade of clinical development of PARP inhibitors in perspective , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[34]  J. R. Dent.  Outpatient , 2018, The Secret History of a Woman Patient.

[35]  M. Espié,et al.  Comparison of clinicopathological (CP) features and outcome of breast cancers (BC) in BRCA-mutation carriers patients, with a family history without BRCA-mutation and with sporadic disease. , 2018 .

[36]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[37]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[38]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[39]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[40]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[41]  B. Monk,et al.  Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. , 2016, The oncologist.

[42]  S. Seal,et al.  Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.

[43]  Y. Drew.  The development of PARP inhibitors in ovarian cancer: from bench to bedside , 2015, British Journal of Cancer.

[44]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[45]  M. Caleffi,et al.  Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care , 2009, BMC Cancer.

[46]  Janice N Cormier,et al.  Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  What is health? , 1999, BMJ.

[48]  J. Beck.  The Government of Nova Scotia , 1957 .

[49]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[50]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[51]  40026386 Return Undeliverable,et al.  Canadian Agency for Drugs and Technologies in Health , 2009 .

[52]  PREVENTING NSAID INDUCED GI COMPLICATIONS: AN ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES IN CANADA February 13, 2007 Canadian Agency for Drugs and Technologies in Health (CADTH) , 2007 .